Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
CAMP4 Therapeutics Corporation ( (CAMP) ) has shared an announcement.
On May 16, 2025, CAMP4 Therapeutics presented promising translational data from its SYNGAP1-related disorders program and urea cycle disorders (UCDs) program at the 28th American Society of Gene and Cell Therapy Annual Meeting. The data showed that CMP-SYNGAP-01 increased SYNGAP1 protein levels in non-human primates and improved disease-relevant phenotypes in mice, while CMP-CPS-001 demonstrated favorable safety and pharmacokinetics in a Phase 1 trial. These findings highlight CAMP4’s potential to address unmet medical needs in genetic disorders and advance its development plans.
The most recent analyst rating on (CAMP) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.
More about CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-targeting therapeutics to upregulate gene expression and restore healthy protein levels. The company aims to treat a broad range of genetic diseases, particularly those characterized by haploinsufficiency or recessive loss of function, using its proprietary RAP Platform™.
Average Trading Volume: 250,072
Technical Sentiment Signal: Strong Sell
Current Market Cap: $37.5M
For a thorough assessment of CAMP stock, go to TipRanks’ Stock Analysis page.